Pharmacologic Considerations in the Management of Patients Receiving Left Ventricular Percutaneous Mechanical Circulatory Support-Reference-Cited by-同舟云学术

Pharmacologic Considerations in the Management of Patients Receiving Left Ventricular Percutaneous Mechanical Circulatory Support

Published:2017-09-19 Issue:10 Volume:37 Page:1272-1283
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Allender J. Erin¹,Reed Brent N.²,Foster Jenna L.³,Moretz Jeremy D.⁴,Oliphant Carrie S.⁵,Jennings Douglas L.⁶,DiDomenico Robert J.⁷,Coons James C.⁸^ORCID

Affiliation:

1. Department of Pharmacy; WakeMed Health & Hospitals; Raleigh North Carolina

2. Department of Pharmacy Practice and Science; University of Maryland School of Pharmacy; Baltimore Maryland

3. Department of Pharmaceutical Services; Palmetto Health Richland; Columbia South Carolina

4. Department of Pharmacy; Vanderbilt University Medical Center; Nashville Tennessee

5. Department of Pharmacy; Methodist Healthcare-University Hospital and University of Tennessee College of Pharmacy; Memphis Tennessee

6. Department of Pharmacy; New York Presbyterian Columbia University Medical Center; New York New York

7. Department of Pharmacy Practice; University of Illinois at Chicago; Chicago Illinois

8. Department of Pharmacy and Therapeutics; University of Pittsburgh School of Pharmacy and UPMC Presbyterian Hospital; Pittsburgh Pennsylvania

Publisher

Wiley

Subject

Pharmacology (medical)

Reference44 articles.

1. 2015 SCAI/ACC/HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care (endorsed by the American Heart Association, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion; affirmation of value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d'intervention);Rihal;Catheter Cardiovasc Interv,2015

2. Decade-long trends (2001-2011) in the incidence and hospital death rates associated with the in-hospital development of cardiogenic shock after acute myocardial infarction;Goldberg;Circ Cardiovasc Qual Outcomes,2016

3. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines;Yancy;J Am Coll Cardiol,2013

4. Temporary percutaneous mechanical circulatory support in advanced heart failure;Brown;Heart Failure Clin,2016

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heparin dosing in patients with Impella-supported cardiogenic shock;International Journal of Cardiology;2023-12

2. The Successful Rotor Wing Transport of 2 Patients Requiring Biventricular Impella Support: A Case Series and Review;Air Medical Journal;2023-11

3. The International Society for Heart and Lung Transplantation/Heart Failure Society of America Guideline on Acute Mechanical Circulatory Support;The Journal of Heart and Lung Transplantation;2023-04

4. The International Society for Heart and Lung Transplantation/Heart Failure Society of America Guideline on Acute Mechanical Circulatory Support;Journal of Cardiac Failure;2023-03

5. Anticoagulation Strategies in Temporary Mechanical Circulatory Support;Current Treatment Options in Cardiovascular Medicine;2023-02-17